This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	<i>Microseminoprotein-β</i> (<i>MSMB</i> ; <i>PSP94</i>); SNP rs10993994	A genomewide association study showed that a SNP in <i>MSMB</i> could be useful for predicting susceptibility to prostate cancer. Loss of <i>MSMB</i> expression was previously shown to be associated with prostate cancer recurrence. Fine-mapping analysis of 6,118 prostate cancer cases confirmed that the rs10993994 SNP in <i>MSMB</i> on chromosome 10q11.2 is significantly associated with prostate cancer risk ($p=8.8\times10^{-18}$). Next steps could include fully characterizing the promoter region of <i>MSMB</i> to determine whether additional variants also influence expression of the gene.	Patent and licensing status undisclosed	Lou, H. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online April 22, 2009; doi:10.1073/pnas.0902104106 Contact: Joseph F. Fraumeni Jr., National Institutes of Health, Bethesda, Md. e-mail: fraumenj@mail.nih.gov
<i>SciBX</i> 2(17); doi:10.1038/scibx.2009.701 Published online April 30, 2009				